Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFR-TKIs Combined With PD-1 Monoclonal Antibody in First-Line EGFR-Mutant Advanced NSCLC
NCT07637448Phase 2Recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- May 2026
- Primary completion
- Mar 2029
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Nanfang Hospital, Southern Medical University. Started May 2026; status: recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07637448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07637448.